Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

Abstract Background PARP inhibitors (PARPi) have recently been approved for various malignancies based on the results of several clinical trials. However, these trials have mostly recruited patients with germline BRCA mutations, and it is unclear whether PARPi have similar efficacy in patients with...

Full description

Bibliographic Details
Main Authors: Ghulam Rehman Mohyuddin, Muhammad Aziz, Alec Britt, Lee Wade, Weijing Sun, Joaquina Baranda, Raed Al-Rajabi, Anwaar Saeed, Anup Kasi
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Cancer
Subjects:
PARP inhibitors
BRCA
Somatic
Germline
Meta-analysis
Online Access:http://link.springer.com/article/10.1186/s12885-020-06948-5

Internet

http://link.springer.com/article/10.1186/s12885-020-06948-5

Similar Items